Dominant Negative Effect As a Novel Mechanism of SPAST Gene Mutation in a Large Family with Hereditary Spastic Paraplegia
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Julien C, Lissouba A, Madabattula S, Fardghassemi Y, Rosenfelt C, Androschuk A
. Conserved pharmacological rescue of hereditary spastic paraplegia-related phenotypes across model organisms. Hum Mol Genet. 2016; 25(6):1088-99.
PMC: 4764191.
DOI: 10.1093/hmg/ddv632.
View
2.
Li L, Yang X
. Tubulin acetylation: responsible enzymes, biological functions and human diseases. Cell Mol Life Sci. 2015; 72(22):4237-55.
PMC: 11113413.
DOI: 10.1007/s00018-015-2000-5.
View
3.
Rehbach K, Kesavan J, Hauser S, Ritzenhofen S, Jungverdorben J, Schule R
. Multiparametric rapid screening of neuronal process pathology for drug target identification in HSP patient-specific neurons. Sci Rep. 2019; 9(1):9615.
PMC: 6610147.
DOI: 10.1038/s41598-019-45246-4.
View
4.
Solowska J, DRozario M, Jean D, Davidson M, Marenda D, Baas P
. Pathogenic mutation of spastin has gain-of-function effects on microtubule dynamics. J Neurosci. 2014; 34(5):1856-67.
PMC: 3905148.
DOI: 10.1523/JNEUROSCI.3309-13.2014.
View
5.
Depienne C, Stevanin G, Brice A, Durr A
. Hereditary spastic paraplegias: an update. Curr Opin Neurol. 2007; 20(6):674-80.
DOI: 10.1097/WCO.0b013e3282f190ba.
View